Adherium’s Smartinhaler Study Shows Big Cuts in Hospitalisations and Costs

The latest update is out from Adherium Ltd. ( (AU:ADR) ).

Adherium reported new real-world data from the iCARE respiratory care study showing its Hailie Smartinhaler platform cut hospitalisations by 67%, reduced length of stay by 57% and lowered total cost of care by 46% for around 850 Intermountain Health patients with asthma and COPD. The study, which supports up to 2,500 patients across five facilities, demonstrated average annual savings of $12,943 per patient, alongside strong adherence levels and sustained 54% engagement over 14 months among a predominantly older, higher-risk population.

These outcomes, presented at the Big Sky Pulmonary Conference, underscore the scalability and economic value of connected inhaler technology and remote monitoring in chronic respiratory disease. Together with the expansion of Adherium’s Remote Patient Monitoring channel, the results strengthen the company’s case for securing value-based contracts, broader reimbursement and expanded sales as U.S. healthcare systems and insurers push for technologies that both improve outcomes and reduce costs.

The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.

More about Adherium Ltd.

Adherium Limited is an ASX-listed medtech company specialising in digital respiratory management solutions for asthma and COPD. Its FDA-cleared Hailie Smartinhaler platform combines connected inhaler sensors with remote patient monitoring and AI-driven engagement tools, targeting improved adherence, reduced hospitalisations and value-based care opportunities, particularly in the U.S. insurance and healthcare markets.

Technical Sentiment Signal: Sell

Current Market Cap: A$10.42M

See more insights into ADR stock on TipRanks’ Stock Analysis page.